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Introduction/Pharmaceutical  
Supply Chain Risk
Introduction to ReMediES and supply network risk
The ReMediES (Reconfiguring Medicines End-to-end Supply) project - 
involving 22 industrial partners comprising global pharmaceutical companies, 
major contract manufacturing organisations, equipment manufacturers, 
and logistics specialists – examined future pharmaceutical supply chains 
supported by novel technology.
These technology interventions spanned the 
end-to-end pharmaceutical supply chain: R&D, 
Primary Manufacturing, Secondary Manufacturing, 
and Distribution to patients. The ReMediES project 
delivered outputs that are captured in Badman and 
Srai (2018) – see academic references at the end  
of this document.
This briefing sets out the key outputs emerging 
from the strand of activity linked specifically to  
the management of pharmaceutical supply risk.
There are multiple challenges involved in the 
supply of pharmaceuticals. Some of these include 
quality and availability of key ingredients, as well  
as issues around the authenticity of drug products. 
The safety and reliability of medicines supply is 
often affected by long lead times, complex global 
manufacturing footprints, and the challenges these 
presents on forecast accuracy. Supply security is 
further compounded by the need to comply with 
strict requirements in manufacturing, and regulatory 
scrutiny that may result in production disruptions.
Risk in this context is often associated with drug 
shortages: events that prevent patients getting  
the right medicines at the right time. In traditional 
supply chains, supply risk is typically managed 
through increased inventory. However, excessive 
inventory is unsustainable, and may conceal the 
variety of factors that may result in supply disruption. 
This project therefore offers multiple lenses  
to focus on pharmaceutical supply chain risk:
1. Real-world data analysis to aid better prediction  
 of disruptions and supply shortages;
2. Expert-driven risk prioritisation, to unravel 
 complex interdependencies between potential  
 causes of supply failure;
3. Simulation-based assessment of new   
 manufacturing technologies to mitigate   
 disruption and reduce inventory.
Outputs are generated at three levels, each 
contributing to more informed risk mitigation:
• Industry-wide: Informing institutional action   
 ahead of disruptive events;
• Commercial Supply Chain: prioritising mitigation  
 actions based on system-wide potential impacts;
• Clinical Supply Chain: Inventory and waste   
 reduction implications from the adoption of   
 Just-in-time production.
Key Outputs
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Predicting Disruption Through  
Incident Data Analysis
The study considered the following datasets:
• Internal company data: collected from supply   
 chain risk experts. 
• Industry wide data: Public domain data from  
 US and EU regulators, which describe:
 • Most frequent root causes.
 • Most influential product and process   
  characteristics.
 • Non-compliance events. 
Across both internal and industry datasets,  
there are some attributed root causes that most 
frequently occur, namely demand variability and 
quality issues. Within quality issues, most are due 
to inadequate procedures, or poor adherence  
to them.
The analysis focussed on two industry incident 
datasets (US FDA Product Shortages and US 
Enforcement Reports) concluding that: 
• Alimentary tract and Metabolism was  
 the most frequently disrupted ATC  
 Therapeutic Area. 
• By dosage form, injectable drugs were the  
 most troublesome across the same two   
 datasets, reflecting the greater challenges   
 associated with sterile manufacturing (see   
 chart opposite). 
Additional evidence from the US FDA Inspection 
results and EMA GMP Non-Compliance reports 
illustrates the influence of geographic location of 
facilities on poor inspection outcomes, in particular, 
China and India are the two countries most likely  
to have adverse results (see map below).
Data Gathering and Analysis
In the last decade the global pharmaceutical market has faced critical 
shortages of certain types of drugs, reaching crisis point in 2011. The number 
of new drug shortages reported annually is on the rise again, prompting the 
study of historical datasets to identify which disruption events and supply 
chain characteristics are most likely to trigger shortages. 
C
ou
rt
es
y 
of
 In
te
rs
ys
 
The disruption that follows an adverse inspection 
outcome should not be underestimated. 
Disruptions are often significant as companies 
attempt to resolve issues, in order to avoid the 
ultimate sanction of regulatory shutdown.
Beyond the contextual factors outlined above, 
analysis of events preceding drug shortages 
yielded further insights on the operational 
triggers contributing to drug shortages.  
These triggers are set out on the next page.
FDA Drug Inspections resulting in OAI (adverse FDA inspections) from 2008 -2017, normalised by #inspections
Colour coding represents; Order of Likelihood;  >8%,  6.5-7.999%,  6-6.499%,  5-5.999%,  <5%)
Key Triggers for Drug Shortages
Events such as Warning Letters, Recalls,  
Import Alerts, Certificate Withdrawals and 
adverse Inspection Results were considered,  
up to 4 years prior to the interruption. This 
represents an upper bound on the time it takes 
to impact the market (due to long cycle times, 
lengthy remediation plans and significant safety 
stock holdings). 
The most frequent ‘triggering event’ was an 
adverse FDA inspection (OAI) which preceded 
69% of individual shortages; 73% if Product 
Discontinuations are excluded. This result 
reflects company responses to an adverse 
inspection result: typically, a company will initiate 
remediation works which will at worst interrupt 
production over months/years, or at best, divert 
scarce resources from normal production 
activities, potentially impacting quality. 
For drugs reported as in shortage or discontinued by the FDA as of August 
2018, further analysis identified linkages to preceding interruption events 
impacting the relevant companies.
Courtesy of Intersys
Of the 33 parent companies reporting  
shortages, 19 experienced major network 
interruptions which resulted in manufacturing 
stoppages or prolonged slowdowns. Downtime 
at each impacted plant often triggered multiple 
drug shortages.
Product discontinuations also appear to be 
influenced by drug pricing. Many ‘hard to  
make’, sterile generics have low, set prices.  
With increasing costs and relatively low  
margins in the generics sector, license holders 
often withdraw from the market, increasing  
the fragility of the supply base. 
In conclusion: drug supply disruptions are 
triggered by a wide variety of complex, often 
interdependent events. However, if a company 
that manufactures injectable drugs in an already 
constrained marketplace, receives an adverse 
inspection report, then that manufacturer should 
be flagged as ‘at risk’ and shortages could be 
expected to follow. 
These insights have been used to support 
risk categorisation and consolidation, with 
an updated risk assessment tool for incident 
monitoring being developed through Intersys 
(available at https://supplychain-risk.com/
regulatory-incident-monitor)
% of FDA Drug Shortages & FDA Enforcement Reports 
(Recalls) by Dosage Form (Top 10)
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Identifying Risk Interdependencies
Defining a sector-wide pharmaceutical supply chain  
risk classification
This activity sought to categorise and prioritise a generic set of risks 
within pharmaceutical supply chains, and then to understand possible 
interdependencies between them. The proposed approach is described 
in details in Settanni et al (2018) – see academic references at the end 
of this document
Risk assessment within the industry typically 
focuses on a specific event within a complex 
manufacturing supply chain. However, mitigation 
strategies should consider multiple events that, 
in combination, may result in significant supply 
failures. These interdependencies may be 
difficult to quantify, and are rarely considered  
by risk professionals.
One of the outputs of this activity was an agreed, 
sector-wide view on risk in pharmaceutical 
supply chains. Risks were identified through 
extensive industry-academic workshop 
discussions, leading to the identification of  
an initial set of 121 risks through the supply  
chain. These were grouped according to 27  
root causes.
The chosen experts represented a typical  
end-to-end pharmaceutical supply chain,  
coming from businesses involved in primary  
and secondary manufacturing, distribution and 
retail pharmacy, as well as risk consultancy.
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Understanding interdependencies between risks:  
A Gamification approach
In a follow-up step, supply chain risk experts 
were asked to identify which risks may influence 
other risks, and what is the magnitude of such 
linkages. Addressing these questions gave a 
deep understanding of possible interactions 
between risk events. 
To facilitate a user-friendly interrogation of risk 
interdependencies, a gamification app (pictured 
left) was developed so that risk experts could 
evaluate the potential 539 links arising from the 
74 risks items identified. 
Expert engagement through the gamification 
app for the assessment of risk interdependencies 
produced a network visualisation of risk 
interdependencies (picture overleaf), and the 
associated network analytics.
A mobile application 
designed to elicit 
knowledge from risk 
management experts
Swipe Left Swipe Right
The direct influence of 
each risk item on any 
other item is related
Risk network visualisation: a) overall interdependencies between risks (the stronger  
the relationship, the darker the arc); b) Detail on sub-network centred on a specific risks
A: B:
The interactive visualisation tool allowed 
the experts to further examine specific risks 
of interest and highlight those most directly 
linked to them. Analytics were deployed to 
compute how risk propagates throughout  
the network, as any risks may in depend,  
or exert an influence on any other. 
The analysis yielded a concise “two-by-two” 
categorisation of the 74 risks (graphically 
plotted below):
I. Upper-Left: Influential risks.
II. Upper-Right: Unstable risks, both influential 
 and dependent.
III. Lower-Right: Dependent risks.
IV. Lower-Left: Mostly autonomous risks.
Risks categorisation plots. Those included in the upper-right quadrant can be unstable  
and difficult to predict, whilst risks in the bottom-left and can be safely discarded
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Evaluating risks and benefits 
in Just-In-Time clinical supply
Inventory in pharmaceutical supply chains 
Conflicting objectives are not uncommon in managing inventories  
in pharmaceutical supply chains: excess stock could improve service; 
however holding inventory is costly, and may eventually result in  
write-offs and disposal of unused medicines.
Project ReMediES has explored a range of 
manufacturing technologies targeting inventory 
reduction whilst improving service to patients.
Within the risk strand, activities were carried 
out to examine trade-offs between service 
improvement and holding inventory. A case 
study in Clinical Trial Supply Chain (CTSC) 
delivering investigation medicinal products 
was considered to test different replenishment 
models. These challenges are of course not 
unique to the CTSC, and can apply to future 
commercial supply chains, particularly due to 
increased personalisation; more responsive 
supply requirements; and potentially more 
distributed manufacturing footprints.
Unlike the analyses presented in the previous 
section, looking at inventory dynamics required 
more detailed, quantitative data. Technical 
details are provided in Settanni and Srai (2018) 
–  see academic references at the end of this 
document.
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A commonly held view is that high availability  
in multiple locations globally is only achieved  
at the expense of efficiency. In current CTSC 
settings, it is not uncommon that less than half  
of manufactured investigational medicine 
products are likely to be used by clinics.
This provides a strong motivation for exploring 
automation and industrial digitalisation 
technologies. An innovative ‘just-in-time’ 
pharmacy concept was tested in a simulation 
environment, comparing the performance of a 
hypothetical CTSC that featured this technology 
intervention, to that of a conventional CTSC. The 
introduction of just-in-time principles, enabled by 
new manufacturing technologies, challenges 
commonly held views on the relationship 
between holding inventory, and attaining high 
service levels.
In particular, expected performance levels  
in terms of inventory emerge from dynamic 
interaction between the demand and supply 
based factors over time.  The following factors 
were included:
– Geographically dispersed demand signals:
 - How the clinical study design develops,
 - Recurrence of clinic visits,
 - Quantity of medicine dispersed.
– Manufacturing capabilities:
 – Cycle times,
 – Inspection outcomes,
 – Replenishment/reorder policies.
Simulating with different assumptions on 
inventory stock levels and logistics policies 
provides sensitivity analysis and revised policy 
holding strategies at the various stock holding 
points. JIT technology interventions, 
demonstrated potential to produce stock near 
on-demand, with potential reductions in unused 
inventory of between 67% to over 80% in the 
particular case considered here.
The “JIT pharmacy” concept 
Concluding remarks  
on pharmaceutical  
supply chain risk 
The work led by the Centre for International Manufacturing in 
collaboration with Intersys and other industry partners, provides  
a multi-disciplinary view on the nature of risk in pharmaceutical  
supply chains: from the statistical analysis of supply disruption  
events, to risk interdependencies across the end-to-end supply  
chain, through to the evaluation of new technology interventions  
in terms of inventory, waste and service levels.
Analysing mitigation strategies is crucial to 
inform supplier selection, order allocation,  
facility locations, inventory levels and overall 
coordination across the supply chain. Insights 
from this research will inform future supply chain 
resilience strategies in medicines manufacturing.
Unlike previous research, pharmaceutical supply 
chain risk was approached from multiple levels 
of analysis – macro (whole sector), meso 
(individual supply chains), and micro (unit 
operations technology. Risks were not considered 
in isolation, rather, they were characterised and 
prioritised based on possible interrelationships 
between them. Supply network design tools 
were deployed to evaluate novel technology 
interventions that challenge commonplace 
trade-offs between economic efficiency and 
medicines overage in CTSC, as well as future 
commercial supply chains. 
As with other strands within ReMediES, this 
activity has benefited from successful pre-
competitive collaboration between industry  
and academia. Building on unprecedented 
engagement with supply chain risk experts,  
and “real-world” data, this research contributes 
to making an impact on industry practice, by 
providing novel approaches and tools to support 
pharmaceutical supply chain risk analysis.
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Centre for International Manufacturing (CIM)
CIM is a research centre at the Institute for Manufacturing 
focusing on strategic and operations management research  
in close collaboration with industrial partners. The Centre  
has developed a strong industrial–policymaking–academic 
community and provides expertise and support in the area  
of international manufacturing and global value networks,  
with particular focus on capability development and strategic 
network design. It provides briefings on globalisation and 
international manufacturing for industry and government.
Institute for Manufacturing (IfM)
The IfM is part of the University of Cambridge’s Department  
of Engineering. It brings together expertise in management, 
technology and policy to address the full spectrum of issues 
which can help industry and governments create sustainable 
economic growth.

